Total trials
172
Active
29
Phase 3
2
Total enrollment
86,185
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sodium-glucose transport-2 (SGLT-2) inhibitors | — | — | — | — | — | 1 | |
| Blood collection for genetic analysis | — | — | — | — | — | 1 | |
| Semaglutide administration plus dietary counselling and physical activity encouragement | — | — | — | — | — | 1 | |
| Semaglutide plus a personalised and supervised program of resistance and endurance training | — | — | — | — | — | 1 |
Next readouts
- 2028-07-31
- 2028-10-31
- 2028-12-31
Top conditions
- Healthy7
- Asthma7
- Breast Cancer6
- Obesity6
- Cardiovascular Disease5
- Takotsubo Cardiomyopathy4
- Type 2 Diabetes4
- Chronic Pain4
Frequently asked questions about University of Aberdeen
- How many clinical trials does University of Aberdeen have on ClinicalTrials.gov?
- University of Aberdeen is listed as the lead sponsor on 172 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Aberdeen's trials are in Phase 3?
- 2 of University of Aberdeen's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Aberdeen focus on?
- University of Aberdeen's most-studied conditions on ClinicalTrials.gov are Healthy, Asthma, Breast Cancer, Obesity, Cardiovascular Disease.
- When are University of Aberdeen's next clinical trial readouts?
- University of Aberdeen has 3 upcoming primary-completion readouts tracked here; the soonest is “Rebalancing the Fat Content of the Heart and Muscles”, expected around 2028-07-31.